Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results
Appointed director

Urovant Sciences Ltd. (UROV) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/08/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
04/01/2021 EFFECT Form EFFECT - Notice of Effectiveness:
03/30/2021 SC 13D/A Sumitomo Chemical Co., Ltd. reports a 100% stake in Urovant Sciences Ltd.
03/29/2021 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
03/29/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/29/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/29/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/29/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/29/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/29/2021 8-K Appointed a new director
Docs: "Amended and Restated Memorandum of Association of Urovant Sciences Ltd",
"Amended and Restated Bye-laws of Urovant Sciences Ltd",
"Sumitovant Biopharma Completes Acquisition of Urovant Sciences"
03/24/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 23, 2021 Urovant Sciences Ltd. Bermuda 001-38667 98-1463899 Suite 1, 3rd Floor 11-12 St. James's Square London SW1Y 4LB United Kingdom Not Applicable +44 207 400 3347 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comm..."
02/19/2021 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
02/19/2021 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
02/16/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/12/2021 10-Q Quarterly Report for the period ended December 31, 2020
02/12/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
02/09/2021 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
02/09/2021 8-K Quarterly results
02/04/2021 GN INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, NHLD, COHR, UROV; Shareholders Are Encouraged to Contact the Firm
02/02/2021 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
01/25/2021 GN SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the Firm
01/08/2021 GN MERGER INVESTIGATION: Halper Sadeh LLP Investigates CBMG, ALSK, UROV, NAV; Shareholders Are Encouraged to Contact the Firm
12/30/2020 GN SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – UROV, EIGI, SNCA, CLCT
12/29/2020 GN SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of UROV, SNSS, TCF, and PS Mergers
12/29/2020 SC 13E3 Form SC 13E3 - Going private transaction by certain issuers:
12/29/2020 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
12/23/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Urovant Sciences Announces U.S. FDA Approval of GEMTESA ® 75 mg Tablets for the Treatment of Patients with Overactive Bladder"
12/22/2020 GN SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies – WDR, WORK, INFO, UROV
12/17/2020 GN SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of WDR, CLCT, NAV, and UROV Buyouts
12/16/2020 GN SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – EIGI, XLNX, UROV, HDS
12/08/2020 GN INVESTIGATION ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – CKH, EIGI, HDS, UROV
12/01/2020 GN Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – NAV, UROV, HDS, AKER
12/01/2020 GN SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of NAV, UROV, AKER, and EMIS Mergers
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy